

CLINICAL POLICY

Droxidopa

Clinical Policy: Droxidopa (Northera)

Reference Number: PA.CP.PMN.17

Effective Date: 01/2018

Last Review Date: 10/2025

Description

Droxidopa (Northera™) is a synthetic amino acid precursor of norepinephrine.

FDA approved indication

Northera is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Northera should be assessed periodically.

Policy/Criteria

** Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria **

It is the policy of PA Health & Wellness® that droxidopa and Northera are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Neurogenic Orthostatic Hypotension (must meet all):

1. Diagnosis of symptomatic nOH caused by one of the following (a, b, or c):
 - a. Primary autonomic failure (Parkinson’s disease, multiple system atrophy, or pure autonomic failure);
 - b. Dopamine beta-hydroxylase deficiency;
 - c. Non-diabetic autonomic neuropathy;
2. Age \geq 18 years;
3. Failure of midodrine or fludrocortisone at up to maximally indicated doses, unless both are contraindicated or clinically significant adverse are experienced;
4. If request is for brand Northera, member must use generic droxidopa, unless contraindicated or clinically significant adverse effects are experienced;
5. Dose does not exceed both of the following (a and b):
 - a. 1,800 mg per day;
 - b. 6 capsules per day.

Approval duration: 14 days

- ##### B. Other diagnoses/indications – Refer to PA.CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

II. Continued Therapy

A. Neurogenic Orthostatic Hypotension (NOH) (must meet all):

1. Previously received medication via PA Health & Wellness benefit or member has previously met initial approval criteria or the Continuity of Care policy (PA.PHARM.01) applies;
2. Member is responding positively to therapy;
3. If request is for brand Northera, member must use generic droxidopa, unless contraindicated or clinically significant adverse effects are experienced;
4. If request is for a dose increase, new dose does not exceed both of the following (a and b):
 - a. 1,800 mg per day;
 - b. 6 capsules per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via PA Health & Wellness benefit or the Continuity of Care policy (PA.PHARM.01) applies and documentation supports positive response to therapy; or
2. Refer to PA.CP.PMN.53 if requested indication is NOT listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

Approval duration: 6 months

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – PA.CP.PMN.53 or evidence of coverage documents**

IV. Appendices/General Information

Appendix A: Abbreviation Key

FDA: Food and Drug Administration
 nOH: Neurogenic orthostatic hypotension
 PD: Parkinson’s disease

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
midodrine	10 mg PO TID at 3 to 4 hour intervals (during daytime hours)	30 mg/day
fludrocortisone	0.05 to 0.2 mg PO QD	0.2 mg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Droxidopa

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): history of hypersensitivity to the drug or its ingredients
- Boxed warning(s): supine hypertension

Appendix D: General Information

- Symptoms of nOH may include lightheadedness, dizziness, visual disturbances, presyncope, and syncope in response to sudden postural change.
- Effectiveness of Northera beyond two weeks of treatment has not been established. Per package labeling for Northera, continued effectiveness of Northera should be assessed periodically.
- The package labeling for Northera includes a Black Box warning for reduction or discontinuation of Northera if supine hypertension cannot be managed by elevation of the head of the bed.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
nOH	100 mg PO TID during the day Titrate to symptomatic response, in increments of 100 mg PO TID every 24-48 hours up to a maximum dose of 600 mg PO TID.	1,800 mg/day

VI. Product Availability

Capsules: 100 mg, 200 mg, and 300 mg

VII. References

1. Northera Prescribing Information. Deerfield, IL: Lundbeck; July 2019. Available at: https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/northera_pi_us_en.pdf. Accessed July 10, 2025.
2. Vijayan J, Sharma VK. Neurogenic orthostatic hypotension - management update and role of droxidopa. *Ther Clin Risk Manag*. 2015 Jun 8;11:915-23.
3. Jones PK, Shaw BH, Raj SR. Orthostatic hypotension: managing a difficult problem. *Expert Rev Cardiovasc Ther*. 2015 Nov;13(11):1263-76. doi: 10.1586/14779072.2015.1095090. Epub 2015 Oct 1.
4. Shibao C, Lipsitz LA, Biaggioni I et al. Evaluation and treatment of orthostatic hypotension. *J Am Soc Hypertens*. 2013 Jul-Aug;7(4):317-24. doi: 10.1016/j.jash.2013.04.006. Epub 2013 May 27.
5. Juraschek SP, Cortez MM, Flack JM, et al. American Heart Association Council on Hypertension. Orthostatic Hypotension in Adults with Hypertension: A Scientific Statement From the American Heart Association. *Hypertension*. 2024 Mar;81(3):e16-e30. doi: 10.1161/HYP.0000000000000236.

Reviews, Revisions, and Approvals	Date
4Q 2018 annual review: changed Initial Approval duration from Length of Benefit to 14 days, and due to lack of evidence of effectiveness of Northera	07/2018

Reviews, Revisions, and Approvals	Date
after 2 weeks of treatment; changed Continued Therapy approval duration from Length of Benefit to 12 months in order to assess for continued efficacy in light of the black box warning potential for severe supine hypertension with use of Northera; removed the requirement to wait 365 days before reauthorizing Northera even in cases where efficacy at 14 days has been demonstrated; changed Continued Therapy approval duration from 14 days to 12 months; references reviewed and updated.	
4Q 2019 annual review: No changes per Statewide PDL implementation 01-01-2020	10/2019
4Q 2020 annual review: Added age limit and references reviewed and updated.	08/2020
4Q 2021 annual review: no significant changes; references reviewed and updated.	10/2021
4Q 2022 annual review: added redirection to generic for brand requests; clarified dosing and quantity limits by separating into separate requirements; references reviewed and updated.	10/2022
4Q 2023 annual review: no significant changes; references reviewed and updated.	10/2023
4Q 2024 annual review: no significant changes; references reviewed and updated.	10/2024
4Q 2025 annual review: no significant changes; added droxidopa to medically necessary statement as generic also requires prior authorization; for continued therapy, extended approval duration from 6 months to 12 months; references reviewed and updated.	10/2025